7-(3-trifluoromethylpyridin-2-yl)pteridin-4-ylamine | 1220632-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 7-(3-trifluoromethylpyridin-2-yl)pteridin-4-ylamine
• 英文别名: 7-[3-(Trifluoromethyl)pyridin-2-yl]pteridin-4-amine
• CAS: 1220632-19-8
• 化学式: C₁₂H₇F₃N₆
• 分子量: 292.223
• InChiKey: GNAHQKSRLXIOBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  90.5
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  对溴三氟甲苯 、 7-(3-trifluoromethylpyridin-2-yl)pteridin-4-ylamine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 8.0h， 以39%的产率得到(4-trifluoromethylphenyl)-[7-(3-trifluoromethylpyridin-2-yl)-pteridin-4-yl]amine
  参考文献：
  名称：

  Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists

  摘要：

  The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation in an attempt to identify novel agents for pain treatment. The design and synthesis of a series of novel TRPV1 antagonists with a variety of different 6,6-heterocyclic cores is described, and an extensive evaluation of the pharmacological and pharmacokinetic properties of a number of these compounds is reported. For example, the 1,8-naphthyridine 52 was characterized as an orally bioavailable and brain penetrant TRPV1 antagonist. In vivo, 52 fully reversed carrageenan-induced thermal hyperalgesia (CITH) in rats and dose-dependently potently reduced complete Freund's adjuvant (CFA) induced chronic inflammatory pain after oral administration.

  DOI：

  10.1021/jm100051g
• 作为产物：
  描述：

  2-bromo-1-(3-trifluoromethylpyridin-2-yl)ethanone hydrobromide 、 4,5,6-三氨基嘧啶硫酸盐 在 barium(II) chloride dihydrate 、 碳酸氢钠 作用下， 以 水 、 1,4-二氧六环 为溶剂， 反应 4.0h， 以23%的产率得到7-(3-trifluoromethylpyridin-2-yl)pteridin-4-ylamine
  参考文献：
  名称：

  Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists

  摘要：

  The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation in an attempt to identify novel agents for pain treatment. The design and synthesis of a series of novel TRPV1 antagonists with a variety of different 6,6-heterocyclic cores is described, and an extensive evaluation of the pharmacological and pharmacokinetic properties of a number of these compounds is reported. For example, the 1,8-naphthyridine 52 was characterized as an orally bioavailable and brain penetrant TRPV1 antagonist. In vivo, 52 fully reversed carrageenan-induced thermal hyperalgesia (CITH) in rats and dose-dependently potently reduced complete Freund's adjuvant (CFA) induced chronic inflammatory pain after oral administration.

  DOI：

  10.1021/jm100051g

文献信息

• Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists
  作者：Charles A. Blum、Timothy Caldwell、Xiaozhang Zheng、Rajagopal Bakthavatchalam、Scott Capitosti、Harry Brielmann、Stéphane De Lombaert、Mark T. Kershaw、David Matson、James E. Krause、Daniel Cortright、Marci Crandall、William J. Martin、Beth Ann Murphy、Susan Boyce、A. Brian Jones、Glenn Mason、Wayne Rycroft、Helen Perrett、Rachael Conley、Nicola Burnaby-Davies、Bertrand L. Chenard、Kevin J. Hodgetts

  DOI：10.1021/jm100051g

  日期：2010.4.22

  The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation in an attempt to identify novel agents for pain treatment. The design and synthesis of a series of novel TRPV1 antagonists with a variety of different 6,6-heterocyclic cores is described, and an extensive evaluation of the pharmacological and pharmacokinetic properties of a number of these compounds is reported. For example, the 1,8-naphthyridine 52 was characterized as an orally bioavailable and brain penetrant TRPV1 antagonist. In vivo, 52 fully reversed carrageenan-induced thermal hyperalgesia (CITH) in rats and dose-dependently potently reduced complete Freund's adjuvant (CFA) induced chronic inflammatory pain after oral administration.